Agreement to file a friendly takeover bid initiated by OncoDNA on IntegraGen to acquire all outstanding shares at a price of 2.20€ per share

Gosselies, Belgium – Évry, France July 9th, 2020

This transaction would bring together OncoDNA’s expertise in oncology precision medicine and IntegraGen’s know-how in DNA sequencing services and bioinformatics analyses. The combination of both companies would enable to offer a complete solution that combines oncology laboratory testing and software solutions which will benefit the treatment of patients with advanced cancer.

You may also be interested in these resources

Scientific Application Note

Cancer Management: Breast Cancer

5 min reading

Jul 24th

What is Breast Cancer? With an estimated 2.26 million new cancer cases and 685 000 deaths in women, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death in 2020,...

Scientific Application Note

IMMUNOTHERAPY The FDA have granted pan-cancer approval for the PD-1 inhibitor pembrolizumab for cancers with tumour mutational burden >10 mut/mb, adult and paediatric.

Jun 22nd

FDA approves pembrolizumab for adults and children with TMB-H solid tumors On June 16, 2020, the Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co., Inc.) for the treatment of adult...

Case of the Month

March: 42-year-old male with a metastatic colorectal cancer

2 min reading

Mar 18th

Here we will describe the case of a man of 42 years old diagnosed in 2021 with metastatic colorectal cancer.